Natriuretic Peptide (ANP) vs Nesiritide (BNP)
Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Natriuretic Peptide (ANP)
0.025–0.050 mcg/kg/min
Nesiritide (BNP)
0.01–0.01 mcg/kg/min
Frequency
Natriuretic Peptide (ANP)
Once daily
Nesiritide (BNP)
Once daily
Administration
Natriuretic Peptide (ANP)
Intravenous infusion (continuous) - standard hospital delivery method
Nesiritide (BNP)
Intravenous (IV) bolus
Cycle length
Natriuretic Peptide (ANP)
Ongoing/indefinite
Nesiritide (BNP)
Ongoing/indefinite
Onset speed
Natriuretic Peptide (ANP)
Moderate (1-2 weeks)
Nesiritide (BNP)
Moderate (1-2 weeks)
Evidence level
Natriuretic Peptide (ANP)
Moderate human trials (Phase 1-2)
Nesiritide (BNP)
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Acute Fluid Management
Hemodynamic Stabilization
Symptom Relief
Rapid Symptom Relief
Fluid Management
Heart Workload Reduction
Compound specifications
Natriuretic Peptide (ANP)
Molecular formula
C127H203N45O39S3
Molecular weight
3080.5 g/mol
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
100% (intravenous administration)
CAS number
Variable depending on salt form; carperitide CAS: 120399-20-4
Nesiritide (BNP)
Molecular formula
C143H244N50O42S4
Molecular weight
3464.0 Da
Half-life
18 minutes (terminal elimination half-life)
Bioavailability
100% (intravenous administration)
CAS number
114471-18-0
Dosing compared
Natriuretic Peptide (ANP)
Intravenous
0.0125 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Very low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
0.025-0.050 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Guideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.
Nesiritide (BNP)
Intravenous
2 mcg/kg IV bolus
Single bolus at initiation · One-time loading dose
FDA-approved Natrecor loading bolus given before the maintenance infusion [5][6]. May be omitted if hypotension risk is high.
0.01 mcg/kg/min continuous infusion
Continuous IV infusion · Typically up to 48 hours
FDA-approved maintenance infusion following the bolus [5][6]. Hospital-only with continuous blood-pressure monitoring.
Best suited for
Natriuretic Peptide (ANP)
Managing acute decompensated heart failure with fluid overload
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. [8][9] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving shortness of breath caused by pulmonary congestion
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. [8] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lowering elevated blood pressure in emergency cardiac situations
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. [5][11] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing the workload on the heart during acute episodes
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. [11][12] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nesiritide (BNP)
Emergency stabilization of acute heart failure episodes
Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Rapid relief of severe shortness of breath
Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hospitalization time and improving outcomes
Nesiritide (BNP) is particularly well-suited for individuals focused on reducing hospitalization time and improving outcomes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing sudden fluid buildup in the lungs or legs
Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Natriuretic Peptide (ANP)
Common
- Mild discomfort at treatment site
- Hypotension (excessively low blood pressure) requiring close monitoring
- Headache and dizziness from sudden blood pressure changes
- Weakness and fatigue during or shortly after treatment
- Nausea and gastrointestinal discomfort
- Decreased kidney function temporarily, requiring follow-up monitoring
- Tremors or shaking sensations
- Atrial fibrillation (irregular heartbeat) in some patients
- Abdominal pain
- Injection site reactions if administered intravenously
- Renal dysfunction with prolonged use, especially in elderly patients
Serious
- Severe allergic reaction
Nesiritide (BNP)
Common
- Headache
- Lightheadedness
- Back pain
Uncommon
- Hypotension (low blood pressure)
- Abdominal pain
- Insomnia
Serious
- Acute kidney injury
- Severe hypotension
- Allergic reaction
Safety & evidence
Natriuretic Peptide (ANP)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) [6][10] providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. [9][10] No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion [5] requires periodic treatment breaks or dose adjustments.
Contraindications
- Severe kidney failure with very low glomerular filtration rate
- Recent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
- Acute coronary syndrome or recent heart attack where vasodilation could be harmful
- Severe hypotension or cardiogenic shock without proper supportive care
- Allergies to ANP, carperitide, or any components of the pharmaceutical formulation
Nesiritide (BNP)
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
FDA-approved nesiritide (Natrecor) demonstrates excellent safety in acute decompensated heart failure with rapid onset (15-minute half-life providing quick reversibility). Symptomatic hypotension occurs in 11% of patients, managed through continuous IV monitoring and dose titration. No serious adverse events, carcinogenicity, or renal dysfunction directly attributable to nesiritide in Phase III trials (n=700+). Tachyphylaxis (tolerance) can develop with prolonged infusions beyond 24-48 hours.
Contraindications
- Systolic blood pressure less than 90 mmHg
- Severe renal impairment or kidney disease
- Cardiogenic shock or severe hypotension
- Allergy to nesiritide or any ingredients
Which is right for you?
Choose Natriuretic Peptide (ANP) if...
- Managing acute decompensated heart failure with fluid overload
- Relieving shortness of breath caused by pulmonary congestion
- Lowering elevated blood pressure in emergency cardiac situations
- Reducing the workload on the heart during acute episodes
Choose Nesiritide (BNP) if...
- Emergency stabilization of acute heart failure episodes
- Rapid relief of severe shortness of breath
- Reducing hospitalization time and improving outcomes
- Managing sudden fluid buildup in the lungs or legs